|
Notes Payable (Details) (USD $)
|
0 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 24, 2016
|
Jul. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2016
|
Dec. 31, 2015
|
Dec. 31, 2014
|
Jul. 31, 2012
Platinum Credit Facility [Member]
|
Dec. 31, 2013
Platinum Credit Facility [Member]
|
Dec. 31, 2012
Platinum Credit Facility [Member]
|
Jul. 31, 2012
Platinum Credit Facility [Member]
U.S. Prime Rate [Member]
|
Jul. 31, 2012
Platinum Credit Facility [Member]
Interest Rate Scenario Three [Member]
|
Dec. 31, 2011
Hercules Loan and Security Agreement [Member]
advance
|
Dec. 31, 2013
Series HH Warrants [Member]
|
Jun. 30, 2013
Series HH Warrants [Member]
|
Dec. 31, 2013
Series GG Warrants [Member]
|
Dec. 31, 2011
Series GG Warrants [Member]
|
Jun. 30, 2013
General Electric Capital Corporation [Member]
installment
|
Jun. 25, 2013
General Electric Capital Corporation [Member]
|
Dec. 31, 2013
General Electric Capital Corporation [Member]
|
Jun. 30, 2013
General Electric Capital Corporation [Member]
Series HH Warrants [Member]
|
Jun. 25, 2013
General Electric Capital Corporation [Member]
Series HH Warrants [Member]
|
Dec. 31, 2011
Hercules Secured Term Promissory Note [Member]
installment
|
Dec. 31, 2011
Hercules Secured Term Promissory Note [Member]
Series GG Warrants [Member]
|
Jun. 24, 2013
Hercules Technology Ii Lp Notes [Member]
|
Jun. 25, 2013
Hercules Technology Ii Lp Notes [Member]
|
Dec. 31, 2012
Hercules Technology Ii Lp Notes [Member]
|
Sep. 30, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
|
Dec. 31, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
|
Jun. 25, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
|
Dec. 31, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
Series X Warrants And Series Aa Warrants [Member]
|
Jun. 30, 2013
Platinum Montaur Life Sciences Llc Credit Facility [Member]
Series X Warrants And Series Aa Warrants [Member]
|
Dec. 31, 2013
Maximum [Member]
|
Dec. 31, 2013
Maximum [Member]
Platinum Montaur Life Sciences Llc Credit Facility [Member]
|
Jun. 30, 2013
Preferred Stock [Member]
|
Dec. 31, 2013
Preferred Stock [Member]
|
Jun. 30, 2013
Common Stock [Member]
|
Dec. 31, 2013
Common Stock [Member]
|
|
| Notes Payable [Line Items] | |||||||||||||||||||||||||||||||||||||||
| Maximum borrowing capacity | $ 50,000,000 | $ 10,000,000 | $ 35,000,000 | ||||||||||||||||||||||||||||||||||||
| Line of Credit Facility, Maximum Number of Advances | 2 | ||||||||||||||||||||||||||||||||||||||
| Current borrowing capacity | 15,000,000 | 7,000,000 | 31,800,000 | ||||||||||||||||||||||||||||||||||||
| Debt instrument, spread on reference rate | 6.75% | 0.125% | 6.75% | 6.75% | |||||||||||||||||||||||||||||||||||
| Debt Instrument, minimum effective interest rate | 10.00% | 10.00% | |||||||||||||||||||||||||||||||||||||
| Warrants, number of securities called by warrants | 301,205 | 301,205 | 333,333 | ||||||||||||||||||||||||||||||||||||
| Warrants, exercise price | 3.39 | 2.49 | 2.10 | 2.49 | 2.49 | 2.10 | 3.83 | ||||||||||||||||||||||||||||||||
| Warrants, expiration date | Sep. 24, 2016 | Jun. 25, 2023 | Dec. 29, 2016 | Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||
| Debt instrument, second advance amount | 3,000,000 | ||||||||||||||||||||||||||||||||||||||
| Monthly Installments | 30 | ||||||||||||||||||||||||||||||||||||||
| Debt instrument, number of periodic installments | 30 | ||||||||||||||||||||||||||||||||||||||
| Debt instrument, frequency of payment | monthly | monthly | |||||||||||||||||||||||||||||||||||||
| Debt instrument, effective interest rate | 9.83% | 10.00% | |||||||||||||||||||||||||||||||||||||
| Amount potentially available on terms to be negotiated | 15,000,000 | ||||||||||||||||||||||||||||||||||||||
| Debt committed upon the approval of Lymphoseek on consistent terms | 20,000,000 | ||||||||||||||||||||||||||||||||||||||
| Amount drawn down during period | 4,000,000 | 4,000,000 | |||||||||||||||||||||||||||||||||||||
| Debt conversion, original debt, amount convertible | 1,500,000.0 | ||||||||||||||||||||||||||||||||||||||
| Beneficial conversion feature | 24,888 | ||||||||||||||||||||||||||||||||||||||
| Provision Effective Period | 0 years 0 months 365 days | ||||||||||||||||||||||||||||||||||||||
| Derivative liabilities | 520,478 | ||||||||||||||||||||||||||||||||||||||
| Debt issuance costs | 593,000 | 881,000 | 691,000 | 593,339 | |||||||||||||||||||||||||||||||||||
| Repayments of Notes Payable | 5,982,155 | 1,285,046 | 62,411 | 1,300,000 | 4,400,000 | 1,300,000 | 4,781,333 | 4,800,000 | |||||||||||||||||||||||||||||||
| Debt instrument, debt discount | 743,062 | 202,287 | 1,900,000 | 1,600,000 | 545,366 | 187,000 | |||||||||||||||||||||||||||||||||
| Unamortized Debt Issuance Expense | 176,000 | ||||||||||||||||||||||||||||||||||||||
| Notes payable | 25,000,000 | 3,200,000 | |||||||||||||||||||||||||||||||||||||
| Percentage of original principal amount of loan to be paid as a fee | 4.00% | ||||||||||||||||||||||||||||||||||||||
| Line of Credit Facility, Covenant Terms | maintains a minimum cash balance greater than six times its monthly cash burn | ||||||||||||||||||||||||||||||||||||||
| Debt Instrument, Convenant Minimum Cash Balance | 22,600,000 | ||||||||||||||||||||||||||||||||||||||
| Debt instrument, end of term fee | 250,000 | ||||||||||||||||||||||||||||||||||||||
| Debt instrument, early payment penalty | 66,000 | ||||||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt | (1,372,266) | 0 | 0 | 429,000 | |||||||||||||||||||||||||||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.80% | 10.00% | |||||||||||||||||||||||||||||||||||||
| Interest rate in addition to amended agreement | 0.125% | ||||||||||||||||||||||||||||||||||||||
| Percentage of VWAP for conversion calculation | 90.00% | ||||||||||||||||||||||||||||||||||||||
| Number of days preceding the date of conversion request | 10 days | ||||||||||||||||||||||||||||||||||||||
| Minimum revenue from sales and licensing for mandatory repayment due | 2,000,000 | ||||||||||||||||||||||||||||||||||||||
| Warrants Not Settleable in Cash, Fair Value Disclosure | 943,000 | ||||||||||||||||||||||||||||||||||||||
| Derivative, Gain (Loss) on Derivative, Net | 106,032 | ||||||||||||||||||||||||||||||||||||||
| Long-term Debt, Fair Value | 4,300,000 | ||||||||||||||||||||||||||||||||||||||
| Conversion of Series B preferred stock to common stock, shares | (2,364.9) | (2,364.9) | |||||||||||||||||||||||||||||||||||||
| Number of common shares underlying Series B Preferred Stock | 7,733,223 | 7,733,223 | |||||||||||||||||||||||||||||||||||||
| Debt Instrument, Face Amount | 25,000,000 | ||||||||||||||||||||||||||||||||||||||
| Shares conversion, number of common stock equivalent to each preferred stock | 3,270 | 3,270 | |||||||||||||||||||||||||||||||||||||
| Interest expense related to debt | 2,800,000 | 1,200,000 | 10,000 | ||||||||||||||||||||||||||||||||||||
| Interest expense related to debt | 765,000 | 545,000 | 4,000 | ||||||||||||||||||||||||||||||||||||
| Principal maturities in 2014 | 4,800,000 | ||||||||||||||||||||||||||||||||||||||
| Principal maturities in 2015 | 9,700,000 | ||||||||||||||||||||||||||||||||||||||
| Principal maturities in 2016 | $ 13,700,000 | ||||||||||||||||||||||||||||||||||||||